Search
AnaptysBio Ord Shs
ANABVAdd to Watchlist
43.800
0.0000.00%
Close 05/20, 16:00（ET）Quotes delayed by 15 min
1.71BMarket Cap
--P/E TTM
More Details of AnaptysBio Ord Shs Company
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
AnaptysBio Ord Shs Info
Ticker SymbolANABV
Company nameAnaptysBio Inc
IPO dateJan 26, 2017
CEOFaga (Daniel R)
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address10770 Wateridge Circle, Suite 210
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone13026587581
Websitehttps://www.anaptysbio.com/
Ticker SymbolANABV
IPO dateJan 26, 2017
CEOFaga (Daniel R)
Company Executives of AnaptysBio Ord Shs
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Mr. Hollings C. Renton
Mr. Hollings C. Renton
Independent Director
Independent Director
--
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
--
--
Dr. J. Anthony Ware, M.D.
Dr. J. Anthony Ware, M.D.
Independent Director
Independent Director
--
--
Dr. Dennis Fenton, Ph.D.
Dr. Dennis Fenton, Ph.D.
Independent Director
Independent Director
--
--
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Dennis M. Mulroy, CPA
Mr. Dennis M. Mulroy, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Paul F. Lizzul, M.D., Ph.D.
Dr. Paul F. Lizzul, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Mr. Hollings C. Renton
Mr. Hollings C. Renton
Independent Director
Independent Director
--
--
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
--
--
Dr. J. Anthony Ware, M.D.
Dr. J. Anthony Ware, M.D.
Independent Director
Independent Director
--
--
Dr. Dennis Fenton, Ph.D.
Dr. Dennis Fenton, Ph.D.
Independent Director
Independent Director
--
--
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Reporting Period
No. of institutions
Shares Held
Proportion
Change
No Data
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
